🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Prilocaine (Hyperbaric 2%)

    United Therapeutics Europe Ltd

    Cervical Incompetence in Pregnancy as Antepartum Condition

    approved small molecule active

    1 trial

  2. Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    approved other terminated

    1 trial

  3. Prothrombin Complex Concentrate, Human

    The First People's Hospital of Lianyungang

    Cardiac Surgical Procedures

    approved small molecule active

    1 trial

  4. Proton Pump Inhibitors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Upper Gastrointestinal Hemorrhage

    approved small molecule active

    1 trial

  5. Qizhitongluo Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    approved small molecule completed

    1 trial

  6. Quick-Acting Heart Reliever

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Stenosis

    approved small molecule completed

    1 trial

  7. RDD to Palynziq

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    approved small molecule active

    1 trial

  8. RF Ablation procedure

    Rhythm Pharmaceuticals Netherlands B.V.

    Paroxysmal Atrial Fibrillation

    approved other completed

    1 trial

  9. RIBOCICLIB, Kisqali 200 mg film-coated tablets

    The George Institute

    Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence

    approved small molecule active

    1 trial

  10. RITALINE L.P. 10 mg, gélule à libération prolongée

    Tour Hekla

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    approved small molecule active

    1 trial

  11. RIVAROXABAN , RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.

    approved small molecule active

    1 trial

  12. RIVASTIGMINE, Rivastigmin adhesive plaster 9.5 mg placebo containing 0 mg of rivastigmin, Rivastigmin adhesive plaster 4.6 mg placebo containing 0 mg of rivastigmin, RIVASTIGMINE

    Disc Medicine

    Depression

    approved small molecule active

    1 trial

  13. RIXUBIS: On-Demand

    Takeda

    Hemophilia B

    approved mab completed

    1 trial

  14. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  15. ROCTAVIAN 2 × 1013 vector genomes/mL solution for infusion

    BioMarin Pharmaceutical Australia Pty Ltd

    Hemophilia A

    approved small molecule active

    1 trial

  16. ROSUVASTATIN AND EZETIMIBE , BEMPEDOIC ACID , ROSUVASTATIN AND EZETIMIBE , ATORVASTATIN AND AMLODIPINE

    The George Institute

    CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus

    approved small molecule active

    1 trial

  17. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze Tollwut-Impfstoff (inaktiviert), RABIPUR, poudre et solvant pour solution injectable en seringue préremplie. Vaccin rabique (inactivé)., Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    rabies pre-exposure prophylaxis

    approved small molecule active

    1 trial

  18. Rabipur, BCG VACCINE AJV por és oldószer szuszpenziós injekcióhoz BCG vakcina, fagyasztva szárított

    Disc Medicine

    health volunteerst

    approved small molecule active

    1 trial

  19. Raltitrexed

    The First People's Hospital of Lianyungang

    Head and Neck Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  20. Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial

  21. Rapid Acting insulin with pre-treatment of rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  22. Rapydan

    Jazz Pharmaceuticals Ireland Limited

    Healthy

    approved small molecule terminated

    1 trial

  23. ReFacto

    Wyeth is now a wholly owned subsidiary of Pfizer

    Hemophilia A

    approved small molecule terminated

    1 trial

  24. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources